Financials data is unavailable for this security.
View more
Year on year AnaptysBio Inc had net income fall 27.11% from a loss of 128.72m to a larger loss of 163.62m despite a 66.78% increase in revenues from 10.29m to 17.16m.
| Gross margin | -- |
|---|---|
| Net profit margin | -289.75% |
| Operating margin | -257.84% |
| Return on assets | -33.78% |
|---|---|
| Return on equity | -161.81% |
| Return on investment | -36.91% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at AnaptysBio Inc fell by 35.34m. However, Cash Flow from Investing totalled 144.75m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 120.80m for operations while cash used for financing totalled 59.30m.
| Cash flow per share | -6.02 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.77 |
|---|---|
| Tangible book value per share | 2.77 |
More ▼
Balance sheet in USDView more
| Current ratio | 10.23 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
